Par'Immune - Crunchbase Company Profile & Funding

Q: Who invested in Par'Immune?

Par'Immune has 2 investors including AGORANOV And Eurasante.

Q: When was the last funding round for Par'Immune?

Par'Immune closed its last funding round on obfuscated from a Non-equity Assistance round.

Overview

Par'Immune

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About Par'Immune

CB Rank

3776640

Par'Immune develops P28GST, a parasite-derived protein used as an immunotherapy to treat autoimmune conditions like Crohn's disease.

Founded

obfuscation

Private

Non-equity Assistance

Marquette Lez Lille, Nord-Pas-de-Calais, France

251-500

www.parimmune.com/

Funding Rounds

Non-equity Assistance

OBF

obfuscation

Non-equity Assistance

OBF

obfuscation

Key People

Abderrahim Lachgar: Chief Executive Officer & Co-founder
Past Role: Invectys Therapeutics, Chief Business Officer
Monique Capron: Chief Scientific Officer & Co-founder

Details

Operating Status

Active

Company Type

For Profit

Founders

Abderrahim Lachgar, Monique Capron

Phone Number

+33 67 778 41 83

Contact Email

contact@parimmune.com

Predictions & Insights

Growth Prediction

See this Growth Prediction

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Non Equity Assistance - Par'Immune	1	obfuscated obfuscation	—	Non-equity Assistance
obfuscated obfuscation	Non Equity Assistance - Par'Immune	1	obfuscated obfuscation	—	Non-equity Assistance
obfuscated obfuscation	Non Equity Assistance - Par'Immune	1	obfuscated obfuscation	—	Non-equity Assistance
obfuscated obfuscation	Non Equity Assistance - Par'Immune	1	obfuscated obfuscation	—	Non-equity Assistance
obfuscated obfuscation	Non Equity Assistance - Par'Immune	1	obfuscated obfuscation	—	Non-equity Assistance

Funding Rounds

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Non Equity Assistance - Par'Immune	1	obfuscated obfuscation	—	Non-equity Assistance
obfuscated obfuscation	Non Equity Assistance - Par'Immune	1	obfuscated obfuscation	—	Non-equity Assistance
obfuscated obfuscation	Non Equity Assistance - Par'Immune	1	obfuscated obfuscation	—	Non-equity Assistance
obfuscated obfuscation	Non Equity Assistance - Par'Immune	1	obfuscated obfuscation	—	Non-equity Assistance
obfuscated obfuscation	Non Equity Assistance - Par'Immune	1	obfuscated obfuscation	—	Non-equity Assistance

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
AGORANOV	—	Non Equity Assistance - Par'Immune	—
AGORANOV	—	Non Equity Assistance - Par'Immune	—
AGORANOV	—	Non Equity Assistance - Par'Immune	—
AGORANOV	—	Non Equity Assistance - Par'Immune	—
AGORANOV	—	Non Equity Assistance - Par'Immune	—